CLINICAL TRIAL — Z-CURCUMIN
CLINICAL TRIAL — Z-CURCUMIN
CLINICAL TRIAL — Z-CURCUMIN
The proof, in people.
The proof, in people.
The proof, in people.
In an independent, double-blind, randomised clinical trial, z-curcumin delivered up to 71× higher bioavailability than native curcumin extract.
In an independent, double-blind, randomised clinical trial, z-curcumin delivered up to 71× higher bioavailability than native curcumin extract.
In an independent, double-blind, randomised clinical trial, z-curcumin delivered up to 71× higher bioavailability than native curcumin extract.
The study
The study
The study
A single 500 mg dose of z-curcumin — as a powder and as an aqueous liquid — compared against 500 mg of native curcumin extract. The core curcumin was identical across all three arms; only the delivery format differed, isolating the effect of zolvia's encapsulation technology.
Plasma curcumin was measured over six hours in healthy adults, and peak concentration (Cmax), time to peak (Tmax) and total exposure (AUC) were compared against the native curcumin.
The trial was conducted independently by Atlantia Food Clinical Trials (Cork, Ireland) under ICH Good Clinical Practice. Pharmacokinetic and statistical analysis was performed independently by StudySetGo.
A single 500 mg dose of z-curcumin — as a powder and as an aqueous liquid — compared against 500 mg of native curcumin extract. The core curcumin was identical across all three arms; only the delivery format differed, isolating the effect of zolvia's encapsulation technology.
Plasma curcumin was measured over six hours in healthy adults, and peak concentration (Cmax), time to peak (Tmax) and total exposure (AUC) were compared against the native curcumin.
The trial was conducted independently by Atlantia Food Clinical Trials (Cork, Ireland) under ICH Good Clinical Practice. Pharmacokinetic and statistical analysis was performed independently by StudySetGo.
A single 500 mg dose of z-curcumin — as a powder and as an aqueous liquid — compared against 500 mg of native curcumin extract. The core curcumin was identical across all three arms; only the delivery format differed, isolating the effect of zolvia's encapsulation technology.
Plasma curcumin was measured over six hours in healthy adults, and peak concentration (Cmax), time to peak (Tmax) and total exposure (AUC) were compared against the native curcumin.
The trial was conducted independently by Atlantia Food Clinical Trials (Cork, Ireland) under ICH Good Clinical Practice. Pharmacokinetic and statistical analysis was performed independently by StudySetGo.
The results
The results
The results
Applying zolvia encapsulation technology to curcumin extract substantially increases oral
bioavailability by 71× (powder) and 66× (liquid) relative to native curcumin extract, regardless of whether the technology is presented in powder or liquid format.
Applying zolvia encapsulation technology to curcumin extract substantially increases oral
bioavailability by 71× (powder) and 66× (liquid) relative to native curcumin extract, regardless of whether the technology is presented in powder or liquid format.
Applying zolvia encapsulation technology to curcumin extract substantially increases oral
bioavailability by 71× (powder) and 66× (liquid) relative to native curcumin extract, regardless of whether the technology is presented in powder or liquid format.
Fig 1 — Plasma curcumin concentration over 6 hours: z-curcumin vs native curcumin control. Independent clinical trial; mean ± SD, n=5 per arm.
Bioavailability vs native (AUC)
Powder
Powder
Liquid
Liquid
Bioavailability vs native (AUC)
Bioavailability vs native (AUC)
71×
71×
66×
66×
Peak concentration (Cmax)
Peak concentration (Cmax)
285.6 vs 4.6 ng/mL
285.6 vs 4.6 ng/mL
305.5 vs 4.6 ng/mL
305.5 vs 4.6 ng/mL
Time to peak (Tmax)
Time to peak (Tmax)
60 vs 360 min
60 vs 360 min
45 vs 360 min
45 vs 360 min
Significance
Significance
p < 0.0001
p < 0.0001
p < 0.0001
p < 0.0001
Both formats were benchmarked separately against native curcumin but the results were descriptively comparable in overall exposure. The liquid format absorbed faster and more uniformly, since it's already in solution, while the powder released more gradually, taking longer to peak but sustaining elevated levels for longer. This slower, sustained release ultimately compensated for the powder's modestly lower peak concentration, resulting in a slight edge in total exposure. Overall, despite differing absorption kinetics, both formats delivered strong and broadly equivalent bioavailability outcomes suggesting that format choice may be guided primarily by customer preference and application, rather than by differences in overall bioavailability.
Both formats were benchmarked separately against native curcumin but the results were descriptively comparable in overall exposure. The liquid format absorbed faster and more uniformly, since it's already in solution, while the powder released more gradually, taking longer to peak but sustaining elevated levels for longer. This slower, sustained release ultimately compensated for the powder's modestly lower peak concentration, resulting in a slight edge in total exposure. Overall, despite differing absorption kinetics, both formats delivered strong and broadly equivalent bioavailability outcomes suggesting that format choice may be guided primarily by customer preference and application, rather than by differences in overall bioavailability.
Both formats were benchmarked separately against native curcumin but the results were descriptively comparable in overall exposure. The liquid format absorbed faster and more uniformly, since it's already in solution, while the powder released more gradually, taking longer to peak but sustaining elevated levels for longer. This slower, sustained release ultimately compensated for the powder's modestly lower peak concentration, resulting in a slight edge in total exposure. Overall, despite differing absorption kinetics, both formats delivered strong and broadly equivalent bioavailability outcomes suggesting that format choice may be guided primarily by customer preference and application, rather than by differences in overall bioavailability.
The scope
The scope
The scope
This was a single-dose, proof-of-concept pharmacokinetic study with five participants per arm. It was designed to measure how curcumin is absorbed, not to assess clinical or health outcomes.
This was a single-dose, proof-of-concept pharmacokinetic study with five participants per arm. It was designed to measure how curcumin is absorbed, not to assess clinical or health outcomes.
This was a single-dose, proof-of-concept pharmacokinetic study with five participants per arm. It was designed to measure how curcumin is absorbed, not to assess clinical or health outcomes.